¿¬¼ö°­ÁÂ
´ëÇÑÀÎÅͺ¥¼Ç¿µ»óÀÇÇÐȸ Á¦32Â÷ Á¤±âÇмú´ëȸ(1ÀÏÂ÷) : 2024-05-24

´ëÇÑÀÎÅͺ¥¼Ç¿µ»óÀÇÇÐȸ Á¦32Â÷ Á¤±âÇмú´ëȸ(1ÀÏÂ÷) : 2024-05-24
±³À°ÀÏÀÚ : 2024-05-24
±³À°Àå¼Ò : ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ 5Ãþ À̺¥Æ®È¦A+B ¿Ü 1°³·ë

±³À°ÁÖÁ¦ : ´ëÇÑÀÎÅͺ¥¼Ç¿µ»óÀÇÇÐȸ Á¦32Â÷ Á¤±âÇмú´ëȸ(1ÀÏÂ÷)

ÁÖÃÖ±â°ü : ´ëÇÑ¿µ»óÀÇÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇÑÀÎÅͺ¥¼Ç¿µ»óÀÇÇÐȸ

´ã´çÀÚ : ÁÖÇýÁ¤
¿¬¶ôó : 02-465-9070

À̸ÞÀÏ : office@intervention.or.kr

±³À°Á¾·ù : ¿µ»óÀÇÇаú

Âü¼®¿¹»óÀÎ : 300¸í
Èñ¸ÁÆòÁ¡ : 3Á¡

Áö¿ª : ºÎ»ê±¤¿ª½Ã
±³À°½Ã°£ : 5 ½Ã°£ 20ºÐ

¼¼ºÎ¼ö°­·á : 120,000¿ø  

ºñ°í »çÀüµî·Ï-Á¤È¸¿ø50000¿ø, Àü¹®ÀÇ100000¿ø, Àü°øÀÇ(¿¬È¸ºñ³³ºÎÀÚ)¹«·á, Àü°øÀǹװøº¸ÀÇ 30000¿ø, ÁØȸ¿ø¹×±âŸ 50000¿ø/ÇöÀåµî·Ï-Á¤È¸¿ø70000¿ø, Àü¹®ÀÇ120000¿ø, Àü°øÀÇ(¿¬È¸ºñ³³ºÎÀÚ)¹«·á, Àü°øÀǹװøº¸ÀÇ 50000¿ø, ÁØȸ¿ø¹×±âŸ 70000¿ø


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±âŸ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 12:50~13:00 Opening Remarks ()

±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 13:00~13:15 ´ëÇ÷°ü ¼Õ»óÀÇ ÀÎÅͺ¥¼Ç ÃÖÅ¿ø(¾ÆÁÖÀÇ´ë)

±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 13:15~13:30 º¹ºÎ ¼Õ»óÀÇ ÀÎÅͺ¥¼Ç ¼­»óÇö(¿ø±¤ÀÇ´ë)

±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 13:30~13:45 °ñ¹Ý/¿äµµ ¼Õ»óÀÇ ÀÎÅͺ¥¼Ç ȲÁ¤ÇÑ(°¡ÃµÀÇ´ë)

±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 13:45~14:00 ¿Ü»ó¿Ü°úÀÇ°¡ ¹Ù¶óº» ÀÎÅͺ¥¼Ç¿µ»óÀÇÇÐÀÇ ÇöȲ°ú ¿ªÇÒ ¹ÚÂù¿ë(¼­¿ïÀÇ´ë)

ÈÞ½Ä 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 14:00~14:20 Coffee break ()

±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 14:20~14:35 Current status of anticancer agents for cTACE in Korea ÀÌÀÎÁØ(±¹¸³¾Ï¼¾ÅÍ)

±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 14:35~14:50 Idarubicin: an alternative to dox in cTACE ÃÖÁø¿ì(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 14:50~15:05 Cisplatin-based cTACE ±èÁøÇü(¿ï»êÀÇ´ë)

±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 15:05~15:20 The role of DEB-TACE and bland embolization as alternative to cTACE À̺´Âù(Àü³²ÀÇ´ë)

Åä·Ð 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 15:20~15:40 Panel discussion: Without Dox powder, what will be the approach for TACE? ()

ÈÞ½Ä 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 15:40~16:00 Coffee break ()

±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 16:00~16:20 Biliary stone removal using balloon catheter, stone basket ±è¼öÈ£, À±Á¾Çõ(°¡Å縯ÀÇ´ë, °í½ÅÀÇ´ë)

±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 16:20~16:40 GB stone removal technical tips, Biliary stone removal using ERCP and SpyGlass ±è¿µÈ¯, ÀÌ»óÈÆ(°è¸íÀÇ´ë, °Ç±¹ÀÇ´ë)

±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 16:40~17:00 Biliary stone: surgical consideration À¯Áø¼ö(¼º±Õ°üÀÇ´ë)

ÈÞ½Ä 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 17:00~17:10 Coffee break ()

±âŸ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ À̺¥Æ®È¦A+B 17:10~17:20 What¡¯s new ()

±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ ÄÁÆÛ·±½ºÈ¦C+D 14:20~14:32 (±¸¿¬¹ßÇ¥) Evaluation of patients undergoing Thoracic endovascular aortic repair for blunt thoracic aortic injury at a level 1 trauma center: Short term outcomes on left subclavian artery preservation with short proximal landing zones ±è¿ëÈÆ(¾ÆÁÖÀÇ´ë)

±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ ÄÁÆÛ·±½ºÈ¦C+D 14:32~14:44 (±¸¿¬¹ßÇ¥) Resorbable, Spherical Gelatin Particles versus Tris-Acryl Gelatin Microspheres for Uterine Artery Embolization: Randomized Controlled Trial ±è¸¸µæ(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ ÄÁÆÛ·±½ºÈ¦C+D 14:44~14:56 (±¸¿¬¹ßÇ¥) The safety and efficacy of preoperative embolization in patients with bladder cancer, above T2 or VI-RADS 3 on CT and MRI: A Propensity Score-Matched Study ÀÌÈ£ÁØ(ºÎ»êÀÇ´ë)

±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ ÄÁÆÛ·±½ºÈ¦C+D 14:56~15:08 (±¸¿¬¹ßÇ¥) Clinical factors associated with femoral artery pseudoaneurysm after femoral access for interventional procedures ½Åº´±Ç(ÀüºÏÀÇ´ë)

±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ ÄÁÆÛ·±½ºÈ¦C+D 15:08~15:20 (±¸¿¬¹ßÇ¥) Ultrasound-Guided Femoral Branch Block for Femoral Arterial Access in Endovascular Aneurysm Repair: A Study on Analgesic Efficacy and Safety Á¶¿µÁ¾(¿ï»êÀÇ´ë)

±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ ÄÁÆÛ·±½ºÈ¦C+D 16:00~16:24 Diagnostic imaging of lymphatic disease: MR lymphangiography, CT lymphangiography Çã¼¼¹ü, ½ÅÁöÈÆ(¼­¿ïÀÇ´ë, ¿ï»êÀÇ´ë)

±³À°½Ã°£ 05¿ù 24ÀÏ ºÎ»êÇ×±¹Á¦Àü½ÃÄÁº¥¼Ç¼¾ÅÍ ÄÁÆÛ·±½ºÈ¦C+D 16:24~17:00 Treatment of chylothorax, traumatic chylous ascites, pelvic leaks and lymphoceles Çöµ¿È£, ±èÁø¿ì, ±è°æ¹Î(¼º±Õ°üÀÇ´ë, ¾ÆÁÖÀÇ´ë, ¿¬¼¼ÀÇ´ë)

 

  • ÃßõÇϱâ
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù.
¡å
ÀÛ¼ºÀÚ   ºñ¹Ð¹øÈ£
 
¿¬¼ö°­Á ÁÖ°£º£½ºÆ®
Á¦¸ñ

[±¤ÁÖ] ´ëÇѽŰæ¿Ü°úÇÐȸ Á¦42Â÷ Ãá°èÇмú´ëȸ_2nd day : 2024-04-26

±³À°ÀÏÀÚ : 2024-04-26 ±³À°Àå¼Ò : ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç ¼¾ÅÍ ÄÁº£¼Ç Ȧ ¿Ü 8°÷ ±³À°ÁÖÁ¦ : ´ëÇѽŰæ¿Ü°úÇÐȸ Á¦42Â÷ Ãá°èÇмú´ëȸ_2nd dayÁÖÃÖ±â°ü : ´ëÇѽŰæ¿Ü°ú

Ãßõ¼ö : 0 , Á¶È¸¼ö : 5,211 , ´ñ±Û¼ö : 0

[¼­¿ï] ½ÉÀå´ë»çÁõÈıºÇÐȸ 2024 7th APCMS (Asia-Pacific CardioMetabolic Syndrome) CONGRESS (1ÀÏÂ÷) : 2024-04..

±³À°ÀÏÀÚ : 2024-04-26 ±³À°Àå¼Ò : Conrad Hotel Seoul (5F PARK BALLROOM) ±³À°ÁÖÁ¦ : 2024 7th APCMS (Asia-Pacific

Ãßõ¼ö : 0 , Á¶È¸¼ö : 5,597 , ´ñ±Û¼ö : 0

[¼­¿ï] 2024 ½ÉÀå»öÀü¿¬±¸È¸ ½ÉÆ÷Áö¿ò : 2024-03-30

±³À°ÀÏÀÚ : 2024-03-30 ±³À°Àå¼Ò : »ï¼º¼­¿ïº´¿ø ÀÏ¿ø¿ª»ç Bµ¿ 9Ãþ È÷Æ÷Å©¶óÅ×½ºÈ¦ ±³À°ÁÖÁ¦ : 2024 ½ÉÀå»öÀü¿¬±¸È¸ ½ÉÆ÷Áö¿òÁÖÃÖ±â°ü : ´ëÇѳúÁ¹ÁßÇÐȸ ½ÃÇà±â°ü(ÁöºÎ/

Ãßõ¼ö : 0 , Á¶È¸¼ö : 5,476 , ´ñ±Û¼ö : 0

[¼­¿ï] (¿Â¶óÀÎ)Á¦27Â÷ ´ç´¢º´ ±³À°ÀÚ ¿¬¼ö°­Á : 2024-03-30

±³À°ÀÏÀÚ : 2024-03-30 ±³À°Àå¼Ò : ¿Â¶óÀÎ »ýÁß°è ±³À°ÁÖÁ¦ : (¿Â¶óÀÎ)Á¦27Â÷ ´ç´¢º´ ±³À°ÀÚ ¿¬¼ö°­ÁÂÁÖÃÖ±â°ü : ´ëÇÑ´ç´¢º´ÇÐȸ ´ã´çÀÚ : °û¼ÖÀÌ ¿¬¶ôó : 02-71

Ãßõ¼ö : 0 , Á¶È¸¼ö : 5,607 , ´ñ±Û¼ö : 0

[¼­¿ï] (¿Â¶óÀÎ) 2024³â Á¦5ȸ ½Å¼ººóÇ÷¿¬±¸È¸ ¿¬¼ö°­Á : 2024-03-09

±³À°ÀÏÀÚ : 2024-03-09 ±³À°Àå¼Ò : (¿Â¶óÀÎ) ±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) 2024³â Á¦5ȸ ½Å¼ººóÇ÷¿¬±¸È¸ ¿¬¼ö°­ÁÂÁÖÃÖ±â°ü : ´ëÇѽÅÀåÇÐȸ ½ÃÇà±â°ü(ÁöºÎ/°ú) : ½Å¼ººóÇ÷¿¬

Ãßõ¼ö : 0 , Á¶È¸¼ö : 5,453 , ´ñ±Û¼ö : 0